DDInter1581 DDInter1435
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Repaglinide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Repaglinide {u} (Compound) binds {v} (Gene) ABCC8
Repaglinide {u} (Compound) is included by {v} (Pharmacologic Class) Potassium Channel Antagonists
Repaglinide {u} (Compound) downregulates {v} (Gene) DNMT3A
Repaglinide {u} (Compound) causes {v} (Side Effect) Ischaemia
Repaglinide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methylcellulose
Repaglinide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxandrolone
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bempedoic acid
Repaglinide {u} may lead to a major life threatening interaction when taken with {v} Gemfibrozil
Repaglinide (Compound) treats type 2 diabetes mellitus (Disease)
Repaglinide (Compound) binds ABCC8 (Gene)
Repaglinide (Compound) is included by Potassium Channel Antagonists (Pharmacologic Class)
Repaglinide (Compound) downregulates DNMT3A (Gene)
Repaglinide (Compound) causes Ischaemia (Side Effect)
Repaglinide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Repaglinide may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Repaglinide may lead to a major life threatening interaction when taken with Gemfibrozil